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Abstract 
Down syndrome (DS) is the most common genetic cause of intellectual disability (ID) in 
humans with an incidence of approximately 1:1000 live births worldwide. It is caused by the 
presence of an extra copy of all or a segment of the long arm of human chromosome 21 (trisomy 
21). People with DS present with a constellation of phenotypic alterations involving most organs 
and organ systems.  ID is present in all people with DS, albeit with variable severity.  DS is also 
the most frequent genetic cause of Alzheimer’s disease (AD) and approximately 50% of those 
with DS will develop AD-related dementia.  In the last few years, significant progress has been 
made in understanding the crucial genotype-to-phenotype relationships in DS, in identifying the 
alterations in molecular pathways leading to the various clinical conditions present in DS, and in 
preclinical evaluations of potential therapies to improve the overall health and wellbeing of 
individuals with DS. In June 4-7 of 2015, 230 scientists, advocates, patients and family members 
met in Paris for the 1st International Conference of the Trisomy 21 Research Society.   Here, we 
report some of the most relevant presentations that took place during the meeting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
The Trisomy 21 Research Society (T21RS) recently held the first meeting in its history. 
This International Conference took place in June 4-7 of 2015 at the Brain and Spine Institute in 
Hospital Pitié-Salpêtrière in Paris. The meeting, entitled “Changing paradigms in Down 
syndrome” attracted 230 participants from 20 countries including scientists, clinicians and 
members of associations and foundations.  This report documents some of the most salient 
research and clinical developments presented during the meeting.  
Katheleen Gardiner (USA), Roger Reeves (USA) and John Hardy (UK) delivered the initial talks 
that served as a comprehensive summary of the current state of knowledge regarding Down 
syndrome (DS). Dr. Gardiner reviewed the gene content of Hsa21, emphasizing what is now 
known about long non-coding RNA genes and the conservation of protein coding genes in 
orthologous mouse genomic regions (Gupta et al 2016). Dr. Gardiner also showed new data on 
the extensive differences, in protein expression in several brain regions, between male and 
female DS mice trisomic for the Hsa21 orthologous region on mouse chromosome 10 (Mmu10). 
The Mmu10 syntenic segment encodes four proteins with known sex-specific functions; these 
must be considered candidates for causing possible sex differences in DS in phenotypic features, 
including responses to therapeutic interventions. In an homage to Dr. Muriel Davisson who 
created it, Dr. Reeves reviewed the history of the Ts65Dn, the first viable segmental trisomy 
mouse model of DS, and the inestimable value of its role in furthering DS research. Dr. Reeves 
also reviewed his research on cerebellar abnormalities in the Ts65Dn, the role of sonic hedgehog, 
and the use of zebrafish to identify candidate causative genes. He further described initial 
comparison of the Ts65Dn features with those of the newer Dp(16)1Yey DS mouse model that is 
trisomic for the entirety of the Mmu16 Hsa21 syntenic region. Dr. Hardy reviewed efforts to 
study the genetics of Alzheimer’s disease (AD) in DS, touching on the concept that all 
individuals with DS indeed develop AD dementia, the role ApoE4 allelic variation, and 
describing the LonDownS consortium which is collecting samples from individuals with DS at 
multiple ages and carrying out SNP analysis. 
 
Neuropathology in the adult with DS 
Life expectancy and quality of life for individuals with DS have dramatically improved in 
recent years. However, with increasing age pathological dysfunctions are exacerbated including 
the development of AD neuropathology in nearly all individuals with DS, and dementia in 
almost half of individuals with DS age 50 and older.   
Elizabeth Head (USA) focused on white matter integrity and cerebrovascular pathology 
in older subjects with DS as part of a longitudinal study of aging and dementia.  Using diffusion 
tensor imaging, Head and colleagues showed that frontal white matter integrity is significantly 
lower in DS compared to non-DS controls, and is further compromised in DS dementia and 
correlated with neuropsychological test scores. The results linked white matter loss with 
vasculature changes and/or neuroinflammation in DS, both of which are under current 
investigation.    
Stanley Durrleman (France) presented an alternative approach for the analysis of 
variations of the neuroanatomical phenotype specifically analyzing the shape of deep brain 
structures. This approach relies on the estimation of one or several reference anatomical 
configuration(s) specific to a group of subjects. The anatomical configuration of each subject is 
compared to the reference(s) via spatial deformations.  This method allows 
differences between subjects or between populations as typical deformations of their brain 
structures.   
Besides the anatomical shape, understanding the role and importance of connectivity 
patterns is crucial.  Pathologies in intellectual disabilities present with characteristic alterations in 
neuronal structure and connectivity leading to changes in neuronal network dynamics and 
function.  To systematically analyze short and long-range connectivity patterns, Dr. Mara 
Dierssen (Spain) presented examples in mouse models of DS (Ts65Dn and TgDYRK1A) that 
recapitulate both cognitive impairment and morphological alterations observed in DS. . 
The deregulation of broad protein networks driven by a broad transcriptional deregulation 
as consequence of trisomy 21 is a field of intense research. V. Hindie (France) presented a DS-
related protein interaction map generated using high-throughput, domain-based yeast two-hybrid 
technology. Fifty-two human proteins, selected for their putative role in DS and associated 
intellectual deficiency were used as entry points to screen a random-primed adult brain cDNA 
library. More than 1200 protein-protein interactions were identified and integrated with protein 
interaction data from the literature.  This will eventually make possible the creation of a 
comprehensive interaction map centered on DS proteins.  
In analysis of brain tissue from DS patients with and without AD,  Marzia Perluigi (Italy) 
showed that pathological hallmarks common to DS and AD, that include plaque deposition, 
neurofibrillary tangles, oxidative damage, and impaired mitochondrial function, are all related to 
oxidative stress (OS).   While a low amount of OS can activate protective cellular mechanisms, 
such as the antioxidant and heat shock responses, cell cycle regulation, DNA repair, unfolded 
protein response and autophagy, chronic OS causes irreversible damage to intracellular 
macromolecules including protein oxidation. Accumulation of damaged proteins, increasingly 
prone to aggregation, appears to be a key factor leading to neuronal death.   
 Finally, Cynthia Lemere (USA) presented evidence that, although the onset of AD 
pathogenesis varies in DS brains, intracellular Aβ42 precedes deposition of extracellular diffuse 
Aβ42 plaques, which is followed by plaque maturation, neuritic dystrophy, inflammation, 
vascular amyloid and the formation of NFTs in neocortex. It is still unclear which factors 
determine the timing of the onset of AD pathology in DS or the tipping point for clinical 
dementia.  
 
Beyond neuropathology and cognition 
 John O’Bryan (USA) discussed the role of the intersectin 1 (ITSN1) scaffold protein in 
DS-associated malignancies. ITSN1 is overexpressed in DS patients and the O’Bryan group 
previously demonstrated that ITSN1 activates the Ras proto oncogene on endocytic vesicles. He 
presented data on the fabrication and properties of a novel, protein-based inhibitor of Ras. This 
engineered protein selectively bound Ras and inhibited it ability to activate downstream 
signaling pathways such as the ERK-MAPK. In addition, this Ras inhibitor blocked Ras-
mediated transformation. O’Bryan also discussed potential mechanisms by which this engineered 
protein inhibited Ras function and how such inhibitors might be relevant to DS-associated 
cancers. (But cancer is rare in DS?) 
 S. Ogawa (Japan) presented an analysis of genomic mutations present in DS-acute 
megakaryoblastic leukemia (DS-AMKL). While DS patients exhibit a reduced incidence of solid 
tumors, they have an elevated risk for leukemias. Approximately 5% of DS children develop a 
transient myeloproliferative disorder (TAM) at birth. All of these patients possess mutations in 
the GATA1 transcription factor. While this TAM resolves in most cases, roughly 20% progress 
to DS-AMKL. Ogawa has identified additional mutations present in DS-AMKL, but not TAM, 
in components of the cohesion complex (STAG2, RAD21, SMC1A and SMC3). Genetic 
modeling of these mutations in mice revealed that loss of STAG2 increased myeloid 
proliferation and conditional deletion of SMC3 increased the hematopoietic stem cell and 
progenitor populations.  
 John Crispino (USA) presented work on the dual-specificity tyrosine regulated kinase 
DYRK1A in normal and malignant hematopoiesis. His lab previously described a tumor-
promoting role for DYRK1A in DS-AMKL, although its role in normal hematopoiesis was 
unclear. Here, he showed, using conditional DYRK1A mouse models (CKO), that loss of 
DYRK1A resulted in defects in both B- and T-cell lineages without affecting myeloid 
development. These results were mimicked by pharmacological inhibition of DYRK1A with 
EHT-1610. CKO lymphoid cells failed to exit the cell cycle and exhibited defects in DREAM 
targets with increases in phospho-Rb, Cyclin D2 and Cyclin D3.  Given the high expression of 
Dyrk1A in B- and T- lineage ALL, they tested the efficacy of DYRK1A inhibition and found 
that EHT-1610 inhibited the growth of both B-ALL and T-ALL suggesting DYRK1A inhibitors 
may be efficacious in these malignancies.  
 Michel Polak (France) presented results on the role of DYRK1A in thyroid dysfunction 
in DS. , His lab found that a BAC transgenic Dyrk1A mouse model with 3 copies of DYRK1A 
exhibited a decrease in thyroglobulin-positive surface area, a decrease in T4 levels and an 
increase in TSH levels compared to wild type control mice. The thyroid showed the same degree 
of abnormal morphogenesis as observed with in human fetuses with DS. Although DYRK1A 
was sufficient for this hypothyroid phenotype it was not clear whether DYRK1A was necessary 
for this thyroid dysfunction in the context of any mouse model of DS, such as Ts65DN or Ts1Cje. 
 L. Rachdi (France) presented another vignette on DYRK1A but in the context of 
pancreatic β cell function. DS children have ~4-fold increased risk for Type 1 diabetes mellitus 
(T1D). Using a combination of mouse models, they demonstrated that haploinsufficiency of 
DYRK1A induces diabetes through decreasing β cell mass. In contrast, Dyrk1A overexpression 
in mBACTg DYRK1A mice results in increased β cell mass. These latter mice were lean and 
resistant to high fat diet-induced β cell failure. DYRK1A overexpression appeared to function 
through increasing the pancreatic progenitor population.  
 D. Keating (Australia) talked about the identification of genes involved in insulin 
secretion and diabetes. As discussed previously by Rachdi, diabetes is more prevalent in DS 
patients. By comparing the glycemic status of different DS mouse models, they identified a 
region of chromosome 21 containing 38 genes that contribute to hyperglycemia and poorer 
glucose tolerance. RCAN1 was identified as the lead candidate. RCAN1 overexpression in mice 
resulted in decreased circulating insulin levels, β-cell area and number, and β proliferation. 
Furthermore, remaining β cells display decreased glucose-stimulated insulin secretion. The 
involvement of RCAN1 in insulin secretion appears to be linked to mitochondrial function.  
 Eva Lana-Elola (UK) introduced the audience to the study of atrio-ventricular septal 
defects (AVSD), commonly present in DS.  To identify the genomic region(s) that contain genes 
causing these congenital heart defects Lana-Elola and co-workers generated a new panel of 
mouse lines that are trisomic for subsets of HSA21-orthologs on mouse chromosome 16.  She 
demonstrated that AVSDs are caused by a third copy of at least two different genes. 
 
Biomarkers of pathology progression in DS 
 Yann Hérault (France) discussed new models of DS with segmental duplication including 
regions of mouse chromosome 17 (Dup17 or Ts1Yah) orthologous to Hsa21. Mouse models 
allow identification of deregulated pathways for further studies on therapeutic interventions and 
selection of biomarkers. The Ts1Yah mice show recognition memory deficits that can be 
compensated by either decreasing the number of copies of the Cbs gene from 3 to 2 or by 
increasing DYRK1A thus highlighting interactions between these two crucial genes, Cbs and 
DYRK1A. 
 Elliot Mufson (USA) showed that AD pathology in DS and in non-DS AD show 
similarities including decreased numbers of magnocellular cholinergic neurons, decreased levels 
of TrkA in temporal cortex, and increased levels of pro NGF and MMP9. There were, however, 
marked differences in the number of thioflavin-positive neurons and the distribution of tangles 
with close proximity to amyloid plaques and dystrophic neuritis, suggesting that DS neurons 
generate a different response to amyloid load. 
 Fabian Fernandez (USA) presented new circadian biomarkers in DS. He studied 2-4 year 
old subjects with DS who exhibit weaker circadian rhythm activities as compared to typically 
developing children. DS is associated with decreased intraday activity consolidation and 
decreased ultradian rhythm patterns of behavioral activity. 
 Nathalie Janel (France) proposed DYRK1A as a new plasma biomarker in DS and AD. 
Indeed, DYRK1A was found in plasma and its level is correlated to the number of copies of the 
corresponding gene. Interestingly, two independent cohorts of AD patients showed a significant 
decrease of DYRK1A plasma levels during progression of the disease which correlated to 
amyloid load in the brain and cognitive impairment. 
 Peter De Deyn (The Netherlands) showed that the level of biogenic amines in plasma of 
DS subjects correlates with the behavioral and psychological symptoms of dementia.  In 
particular, 3-methoxy-4-hydroxyphenylglycol (MHPG) appeared to predict the conversion to AD 
dementia in those with DS. 
 Florencia Iulita (Canada) expanded on the potential of plasma amyloid-beta (Ab) as a 
biomarker for AD in DS. In her study, plasma levels of both Ab40 and Ab42 were elevated in 
demented DS subjects and negatively correlated with cognitive decline in asymptomatic subjects 
without dementia. 
 
Prenatal diagnosis and treatment of DS 
 Tarik Haydar (USA) reported on developmental brain abnormalities in human fetuses and 
in the Ts65Dn and Ts1Cje mouse models (Haydar and Reeves, 2012), including longer 
neurocortical cell cycle, reduced neurogenesis, microcephaly and hypocellularity in the 
neocortex, cerebellum and hippocampus.  He also described recent experiments that 
unexpectedly showed that the Dp (16)1Yey/+ mouse model does not have prenatal abnormalities 
in forebrain growth or morphology, nor reduced neurogenesis or abnormal mitotic activity. 
Along those lines, behavioral abnormalities in this model are not observed until two to three 
weeks of postnatal age.  
 Tomo Tarui (USA) reviewed DS fetal neuropathology, which is characterized by 
microcephaly, overall decreased cell numbers, and decreased cell density and proliferation in the 
second trimester cerebellum and hippocampus. Other prenatal findings in DS include 
disorganized lamination and abnormal neuronal differentiation, accompanied by decreased 
presence of neurotransmitters in frontal lobe.  Abnormal prenatal sonographic findings include 
decreased frontothalamic distances and transcerebellar diameters. Dr. Tarui also presented 
preliminary data from his magnetic resonance imaging study showing that cerebellar growth 
lagged in fetal brains from fetuses with DS. 
 Diana Bianchi (USA) reported on her functional genomic analysis of amniotic fluid 
supernatant cell-free RNA to identify genes that are differentially expressed in living human 
fetuses with trisomy 21 compared to age- and sex-matched fetuses with normal chromosomal 
number (Slonim et al., 2009). Preliminary results from an initial study of apigenin, a natural anti-
oxidant and anti-inflammatory compound found in citrus fruits and leafy green vegetables, given 
at the time of conception and throughout pregnancy to wild-type C57Bl/6 dams mated to Ts1Cje 
males (Guedj et al., 2014) indicate that apigenin improved the time frame of achieving 
developmental milestones for Ts1Cje pups. 
 Renata Bartesaghi (Italy) explained the rationale for using fluoxetine as a treatment for 
DS. The serotonergic system is important for neurogenesis and dendritic development and it is 
altered in DS. She and her colleagues gave fluoxetine to pregnantTs65Dn mice from embryonic 
day 10 to birth to inhibit serotonin re-uptake, and examined short (P2) and long-term (P45) 
outcomes (Guidi et al., 2014, Stagni et al., 2013).  Fluoextine restored overall cellularity and 
connectivity in multiple brain locations.  This effect persisted long-term following treatment 
cessation and was accompanied by significant prevention of cognitive deficits.  
      Jean-Maurice Delabar’s (France) group is focused on ameliorating changes in the 
expression of the Hsa21 kinase, Dyrk1a, which contributes to control of excitation-inhibition 
balance (Guedj et al., 2009, Souchet et al., 2014). They compared three different extracts of 
green tea, the properties of which include inhibition of Dyrk1a, and showed that in 
mBACtgDyrk1a and the Dp(16)1Yey/+transgenic mice, deficits in Y maze performance were 
corrected by treatment with 60 mg/kg/day of green tea extract.  They also tested continuous 
treatment of pregnant mothers throughout gestation until weaning and pups until three months 
after birth. When treatment was stopped at weaning, the effects on density of GAD67 neurons 
and excitation/inhibition balance persisted past the washout phase of the nutritional supplement.  
 Jessica Ash (UK) presented work demonstrating the beneficial effects of maternal choline 
supplementation (MCS) in the Ts65Dn mouse.  Choline is an essential nutrient during fetal 
development due to its role in acetyl choline production, cellular membrane formation, and 
epigenetic regulation.  MCS produced a dramatic improvement in spatial cognition in aged 
Ts65Dn offspring, which correlated with hippocampal neurogenesis (Velazquez et al., 2012) and 
increased density and size of basal forebrain cholinergic neurons (Ash et al., 2014). MCS also 
improved attention and emotional regulation in aged Ts65Dn mice (Moon et al., 2010).   
 In summary, several talks made a strong case for the prenatal period as being one of 
potentially several “windows of opportunity” for treatment of DS. The availability of a prenatal 
treatment option for pregnant women carrying fetuses with DS would significantly change the 
current paradigms of prenatal care (Guedj et al., 2013, Bianchi, 2012). However, fetal 
development is obviously a sensitive time period, and potential adverse effects of treatments 
must be considered carefully. For example, fluoxetine is not even approved for use in children. 
 
From early development to ageing in DS 
 Two breakthrough session covered recent results related to disease phenotypes affecting 
DS individuals across life span. AP Patkee (UK) showed preliminary MRI data indicating 
decreased volumes of the whole brain, and specifically cortex and cerebellum, in DS fetuses, that 
were associated with enlargement of the fourth ventricle.   
M Scarpato (Italy) studied global gene deregulation in DS embryos, with the hypothesis 
that overexpression of chromosome 21 genes may perturb the physiological regulatory mRNA-
miRNA network. Computational analyses selected the HUNK kinase to be the strongest Hsa21 
candidate gene for regulation of  expression of mRNAs and experimental studies have confirmed 
that overexpression of the HUNK 3’ UTR induces an increase in expression of genes involved in 
embryonic stages and decreases corresponding miRNAs. This dysregulation of the mRNA-
miRNAs network may be a partial explanation for the multi system perturbations occurring in 
DS. Abnormal protein maturation has been observed in the DS brain. This is the case for nerve 
growth factor (NGF) where levels are decreased in the brains of AD and DS patients.  Claudio 
Cuello (Canada) reported a significant increase in levels of proNGF and decreases in levels of 
plasminogen and tPA that are involved in the maturation of proNGF. In parallel, mature NGF 
has a decreased half-life due to elevated activity of MMP-9, the major NGF-degrading protease. 
Consequently, resulting decreased levels of mature NGF would contribute to the observed 
atrophy of basal forebrain cholinergic neurons. Alterations in proNGF and MMP-9 were also 
observed in DS neurons in culture, suggesting that the defect in NGF trophic support is an early 
event in DS.  
Dimitry Goldbager (USA) proposed that anomalies in embryogenesis in DS might be 
related to a failure in the mechanism of communication between embryonic and maternal tissues. 
The pericentrin gene, involved in meiosis, mitosis and ciliogenesis, is a candidate for these 
communications.  Mutations in the pericentrin gene cause dwarfism and ciliopathies. Variants of 
this gene in DS have not yet been studied.  
Alexander Kleschevnikov (USA) focused on mechanisms of altered brain functioning in 
the Ts65Dn DS model.  Specifically, the evaluation of the role of the trisomy of the G-protein 
regulated inwardly-rectifying potassium channel KCNJ6 (GIRK2, KIR3.2), by crossing Ts65Dn 
and Kcnj6KO mice to reduce KCNJ6 copy number. This intervention normalized hippocampal 
LTP and some behavioral phenotypes (long-term object recognition memory vs working 
memory).  
During development, the brain chloride gradient is important to drive GABA from 
excitatory to inhibitory and associated to seizure vulnerability. This was the topic of Andrea 
Contestabile (Italy).  After birth in normal brain, the decrease in NKCC1 (Na+-K+-Cl− 1 
cotransporter) and increase in KCC2 (K+-Cl- cotransporter) result in inhibitory GABA. In the 
hippocampal CA1-CA3 of adult Ts65Dn, the potential was found depolarizing, resulting in 
GABA excitation as a result of increased NKCC1 protein. Acute or long-term treatments of 
Ts65Dn mice with bumetanide, an inhibitor of NKCC1, restored the inhibition and their defects 
in the novel-object recognition test (Deidda et al., 2015). Alterations in the excitation/inhibition 
balance due to increased GABAergic signaling have been previously shown in brain of DS 
models. These new data identify a novel therapeutic approach to rescue cognitive abilities in DS.  
The incidence of fractures is elevated in adults with DS resulting from osteoporosis and 
osteopenia. To evaluate these phenotypes in mouse models, Randall Roper (USA) examined 
trabecular bone mineral density, cortical width and biomechanical parameters of the femur in 
Ts65Dn males. The decreases in mineralization, cortical width, bone stiffness and ultimate load 
together with reduced osteoclasts number were rescued by reducing Dyrk1a copy number 
(Ts65Dn x Dyrk1a+/-). Thus, the osteopenic phenotype associated with DS may be rescued 
postnatally by targeting trisomic Dyrk1a.  
Finally, Eugene Yu (USA) presented the study of the mouse model trisomic for all three 
mouse syntenic regions of HSA21 (Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+) to evaluate the 
role of  trisomy in the mechanisms of  myeloproliferative disorder and acute megakaryoblastic 
leukemia observed in DS. The complete trisomy induced splenomegaly and an increase in 
megakaryocyte progenitors related to a Mmu16 region common to in Dp(16)Ye/+ and Ts65Dn. 
Interestingly, adding a GATA1 mutation amplified the effect of the trisomy leading to a more 
severe macrocytic anemia. 
 
Defining translational pathways for DS 
 Susana de la Luna (Spain) reviewed the properties of DYRK1A, a kinase and the most 
popular gene encoded by chromosome 21.  In particular, several neurological phenotypes are 
observed in individuals with reduced expression of DYRK1A, an important fact to consider 
when proposing use of DYRK1A inhibitors in a clinical setting.  Professor de la Luna then 
discussed some of the many nuclear and cytoplasmic targets of this kinase, including RNA 
polymerase II (Di Vona et al., 2015). 
 Weihong Song (Canada) reviewed the role of the enzymes BACE1, the β-secretase that 
cleaves the amyloid precursor protein (APP) to generate Aβ (Zhang et al., 2015), and BACE2, a 
chromosome 21 encoded paralogue of BACE1, which may prevent the formation of Aβ (Sun et 
al. 2006).   The results showed that the chromosome 21 gene RCAN1 modulates the level of APP 
via a differential effect on proteasome activity (Wu et al, 2015). 
 Frances Wiseman (UK) presented results of her work directed at understanding the role 
of Hsa21 genes other than APP in the development of AD pathology and dementia in DS. She 
uses the Tc1 mouse model of DS which is trisomic for 75 % of chromosome 21 genes but not 
APP (Gribble et al., 2013, O’Doherty et al., 2005).  Her results suggest that trisomy of genes 
other than APP can exacerbate Aβ aggregation and deposition, and the associated-cognitive 
deficits seen in a common mutant human APP transgenic mouse model.   
 Ann-Charlotte Granholm-Bentley (USA) continued the theme of mechanisms in AD and 
DS, presenting evidence of the effects of inflammation on cognitive decline in the Ts65Dn 
mouse model of DS (Hunter et al., 2004) and showing that failure of the normal resolution of the 
inflammatory response contributes to disease progression and may be a target for treatment.  
 Marie-Claude Potier (France) talked about her studies of the endosome-lysosome defects 
associated with over-expression of the chromosome 21 gene SYNJ1 which causes endosomal 
enlargement (Cossec et al., 2012). Additionally, up regulation of cholesterol in cellular 
membranes can also cause endosomal enlargement, leading to alterations in APP trafficking and 
processing (Marquer et al., 2014).  
 William Mobley (USA) finished the session with an overview of AD-pathological 
processes that may be amenable to treatment in people with DS including the key role of APP C-
terminal fragments, particularly of ß-CTF in Rab5 activation leading to failure of endosomal 
transport. 
 
Phenotypic studies in DS –animal and cellular models 
 Two presentations reported efforts to identify candidate therapeutic interventions, one for 
the prenatal period and one for aging. Takashi Minami (Japan) used a conditional Dscr1-/- 
mouse model and showed abnormal vascular branch formation in several organs, including the 
brain, and that ApoE protected Dscr1-/- mice against atherosclerotic plaques in aorta. The 
relationship of this approach to therapy for DS is unclear. Heather McGowan (USA) used 
induced pluripotent stem cells (iPSCs) and associated induced neurons (iNs) to study the target 
genes of the five Hsa21 miRNAs; she found that MeCP2 expression is down-regulated in iPSCs 
and iNs from individuals with DS.  Antagonizing HSA21 miRNAs through “Tough Decoy” 
inhibitors normalized iPSCs and iNs MeCP2 expression and synaptic function. Alexandra Botté 
(France) showed that early endosomes are enlarged, form aggregates and their number, as well as 
the number of lysosomes, are increased in cholinergic neurons of adult Ts65Dn mice. Notably, 
the Ts65Dn is trisomic for both SYNJ1 (Hsa21 ortholog) and SYNJ2 (Hsa6 ortholog)(see above, 
regarding SYNJ1 in endosome function and properties). Faycal Guedj (USA) tested the effects of 
prenatal treatment with apigenin on fetal brain gene expression and behavior in the Ts1Cje 
mouse model of DS that is trisomic for approximately 40% of Hsa21 orthologs. Apigenin (400 
mg/kg/day) rescued some features of gene expression and neonatal and adult behavior behavior. 
Eric Hamlett (USA) demonstrated that a one-month treatment of adult Ts65Dn mice with 
Resolvin E1 (5 µg/kg/day), a bioactive pro-resolution ligand, enhanced memory performance in 
the water radial arm maze and novel object recognition tests. This improvement was 
accompanied with a significant reduction of both inflammatory cytokine levels and microglia 
activation.   
 
Behavioral correlates in animal models of DS 
 Marta Fructuoso (Spain) presented her study of feeding behavior, glucose homeostasis 
and endocrine pancreatic functioning in the Ts65Dn mouse model of DS. Young Ts65Dn mice 
on standard chow diet had an increased average food intake and became obese when exposed to 
a high-fat diet, which reflects the higher prevalence of obesity within the DS population.  
 Pratiksha Rao (India) focused on the response time during a dual motor task among 
children with intellectual disabilities. Children with DS were the slowest and had the least force 
during the task when compared to children with intellectual disabilities of another etiology or 
typically developing children.  
 Subsequently, Alain Dekker (The Netherlands) elaborated on behavioral and 
psychological symptoms of dementia (BPSD) in DS. He stressed that particular BPSD are often 
present long before the clinical diagnosis of dementia, and might thus serve as early indicators 
for AD in DS. To accurately assess BPSD in DS, and thus enable adaptive caregiving and early 
therapeutic interventions, Dekker and colleagues developed the novel and all-embracing BPSD-
DS evaluation scale.  
 Thu Lan Nguyen (France) presented her data on behavioral and cognitive improvement in 
mice that overexpressed DYRK1A either alone or in combination with additional HSA21 
orthologs after treatment with Leucettine 41, a specific synthetic DYRK1A inhibitor.  
   
Cognition in DS 
 Annette Karmiloff-Smith (USA) emphasized that endpoint outcomes evolve across 
development, and therefore to really understand the evolution of a disorder, such as AD in DS, 
we need to track the progression of the disease from infancy. Her work, using cutting edge 
methods of eye tracking demonstrates impairments in attention and memory formation as early 
as 6 months in DS.  She also discussed the importance of understanding how impairments in 
basic processes, such as attention and sleep may impact development in other areas, such as 
language. 
 Pamela Banta-Lavenex (Switzerland) presented work teasing apart the spatial navigation 
skills of older children and young adults with DS, finding that this group showed intact 
egocentric search but deficits in allocentric search, reflecting the presence of hippocampal 
deficits in DS. Of interest were the considerable individual differences in search patterns, 
suggesting variation in the development of the hippocampal formation. Very few participants 
with DS were capable of the precision searches that require intact hippocampal development.  
 In a talk focused on language, Len Abbeduto (USA) presented data on a study of 
expressive language sampling (ELS) conducted across 5 sites in the United States. A 
conversation sample, picture book narration, and Autism Diagnostic Observation Schedule were 
administered to all children to assess practice effects and to measure retest-reliability and 
concurrent validity with other commonly used measures. ELS measures had excellent test-retest 
reliability and good concurrent validity, but practice effects were found on the conversation task. 
This consortium will be one of the largest DS cohorts studied for language development to date.  
 Jamie Edgin (USA) presented her data on correlations between sleep and cognitive 
development, showing strong relations between obstructive sleep apnea and reduced expressive 
language and executive function in toddlers and school-age children with DS. Data suggested 
that sleep disturbances in DS are not adequately measured through parent report and that 
objective measures are required. Future studies will examine the timing of the emergence of 
these deficits in infancy and the mechanisms underlying the links between sleep disruption and 
learning deficits.  Nancy Lee (USA) presented her work on measurements of cortical surface 
area and thickness collected in a large sample of children with DS. While she found overall grey 
matter reductions, these reductions stemmed from regional differences in surface area, not 
reductions in cortical thickness, which, conversely, was thicker on average. Surface area 
reductions were most prominent in the frontal and temporal lobes.  
 Debbie Fidler (USA) expanded on our understanding of deficits in executive function in 
DS, which were consistently measured on a number of assessments in early childhood. 
Nonverbal rather than verbal IQ predicted the extent of executive deficits. Given the importance 
of these skills for development in a number of cognitive domains, more work needs to be done to 
translate this aspect of the phenotype into targets of behavioral and pharmacological intervention 
starting early in development.  
 
Impact and strategies for aneuploidy in gene expression and metabolism 
The triplication of HSA21 in DS leads to an increase in gene transcription. To restore the 
expression of particular genes, Marianne Rots (The Netherlands) induced gene reprogramming 
by rewriting epigenetic marks at a genomic locus of interest (Epigenetic Editing). This was 
achieved by engineering DNA binding zinc finger proteins or by employing CRISPR/dCas9 
fused to epigenetic writers/erasers to locally rewrite the epigenetic signature. The results 
successfully demonstrated that rewriting epigenetic marks reprograms gene expression, thus 
offering possibly novel approaches to restore disturbed gene expression profiles. 
Ralph Nixon (USA) presented compelling evidence that APPL1 (adaptor protein 
containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper 
motif) mediates the overactivation of the early endosomal regulator, rab5 in DS and AD.  This is 
caused by increased levels of the β-cleaved carboxy-terminal fragment of APP (βCTF), which 
recruits APPL1 to rab5 endosomes, leading to accelerated endocytosis, endosome swelling and 
impaired axonal transport of rab5-containing endosomes. These effects were corrected in DS 
fibroblasts by APPL1 knockdown. βCTF levels were also found elevated in AD brains. These 
results show that overactivation of rab5 through βCTF-APPL1 interactions constitutes a novel 
APP-dependent pathogenic pathway in DS and AD. 
Jorge Busciglio (USA) discussed recent findings implicating impaired mitochondrial 
metabolism as a key factor leading to common abnormalities in cellular function in three 
different human aneuploidies (trisomies 13, 18 and 21). Mitochondrial-targeted expression of the 
antioxidant enzyme catalase ameliorated both mitochondrial parameters and cellular function as 
measured by in vitro wound healing assays. The results provide further evidence supporting the 
implementation of therapeutic strategies to preserve mitochondrial function and prevent 
oxidative stress in DS. 
Reinier Veitia (France) discussed the molecular and cellular effects of gene dosage 
imbalances, which can lead to abnormal phenotypes when occurring within macromolecular 
complexes and cellular circuits. Potential therapeutic approaches to “buffer” or attenuate the 
abnormal phenotypes include stimulation of mRNA or protein degradation (pharmacological 
modulation of proteolysis), which may help to palliate the deleterious effects of aneuploidy in 
cellular homeostasis. 
 
Clinical evaluation and caring in DS 
 David Stein (USA) searched for factors that are associated with inclusion in the standard 
classroom because it has been shown to improve cognitive development in children with 
DS.  Sixty-three consecutively referred children with DS underwent neuropsychological testing 
in an urban hospital setting .IQ, language, social skills, and adaptive function were examined, as 
well as family socioeconomic status (SES).  Of these possible indicators, only SES powerfully 
predicted inclusion, suggesting that individual needs of children did not determine inclusion 
status in the sample.   
 Obstructive sleep apnea (OSA) is prominent in people with DS with prevalence ranging 
between 55–97%, compared to 1–4% in the typical pediatric population. The objective of Dr. 
Brian Skotko’s (USA) study was to construct a clinically useful a screening tool for OSA by 
using a combination of signs, symptoms, craniofacial anatomical measurements and metabolic 
markers.  They enrolled 130 patients with DS, ages 3–24 years as an observational, prospective 
cohort study.  The significant variables included results of survey questions, medication history, 
anthropometric measurements, vital signs, patient’s age, and physical examination findings.  A 
negative result with their model predicted, with 90% accuracy, that the person does not have 
moderate to severe OSA.  Because of the false positive rate, results need to be confirmed with a 
sleep study. 
 
Assessment of therapeutic approaches and clinical trials for DS 
 M Adorno (USA) reported that Usp16, a HSA21-encoded protein, deubiquinates histone 
H2A, a critical mark for the maintenance of multiple somatic tissues. Increased level of this 
protein is associated with accelerated senescence of Ts65Dn fibroblasts. Down regulation using a 
short interfering RNA rescued abnormalities in stem cells properties and defects in proliferation 
of Ts65Dn and DS fibroblasts (Adorno, M. et al., 2013). Because of its role in controlling 
senescence pathways, Usp16 is an attractive target to potentially ameliorate some of DS 
pathologies. 
 Andre Strydom (UK) described the presentation of dementia in DS, which differs from 
typical AD (Sheehan, R. et al., 2014). He compared criteria used in the International 
Classification of Diseases (ICD-10), the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-TR) dementia criteria, and the DSM-5 for neurocognitive disorder. He presented data 
from LondownS consortium on the floor and ceiling effects of cognitive tests in DS and 
concluded that standardisation of dementia diagnoses is necessary for future trials in older adults. 
 Michael Raffi (USA) presented the DS Biomarker Initiative project which started with a 
pilot study (3 years) on non-demented DS (30-60 years old). Participants underwent extensive 
cognitive testing, and imaging.  Most subjects demonstrated amyloid PET positivity reflecting 
fibrillar amyloid plaque deposition.  Results from multimodal analysis suggest greater 
hippocampal atrophy with amyloid load. Cognitive and functional measures did not correlate 
with amyloid load in DS but did correlate with regional FDG PET measures. He concluded by 
saying that biomarkers of AD can be readily studied in adults with DS and that a multicentre 
longitudinal study should be performed to understand the trajectories of AD markers in DS (Ness 
et al., 2012). 
 Clothilde Mircher (France) started her presentation by highlighting the crucial role of 
thyroid hormone (TH) for brain development and maturation and the consequences of lack of 
folates in malformation and neurocognitive disorders. She also mentioned previous results of 
“ENTRAIN”, a study suggesting a possible synergy between folates supplementation and 
thyroxine (Blehaut et al. 2010). She presented “ACTHYF” a monocentric, random, comparative 
phase III study, in four arms (Folinic acid, TH, both, neither one). At inclusion, patient age 
ranges from 6 to 18 months. Design includes a primary and secondary end points, biometry and 
biological markers.  
 Jeannie Visootsak, (USA) described a clinical trial based upon observations of excessive 
GABAA inhibitory signal in one mice model of DS. She described the properties of the drug 
RG1662 that targets the alpha 5 subunit. She continued her presentation by describing a safety 
study on healthy adults and DS and a study for assessing cognitive tests in teens and adults with 
DS (Visootsak et al., 2011). Then she presented two phase II studies, one on group 12-30 years 
and the other on group 6-11 years. Both multicentric studies will use composite primary end 
points to demonstrate clinically meaningful outcomes. 
 Rafael de la Torre (Spain) presented the third clinical trial of this session: he described 
the rationale to use a DYRK1A inhibitor (Guedj et al., 2009), EGCG in treatment of DS. He 
reminded results of a pilot study using a green tea extract on young adults with DS: safety of 
extract, effects in memory tests, which vanished after discontinuing the treatments. Then he 
described the TESDAD study: a phase II clinical trial, double balanced with placebo. (85 
individuals 18-30 years old) in which placebo and active treatment condition encompasses 
cognitive stimulation. Endpoints included a cognitive test battery (de Sola et al., 2015), imaging 
(Pujol et al., 2015) and biomarkers Noll et al., 2009). Clinical global index shows an effect of the 
treatment, which is maintained 6 months after interruption of the treatment, which also rescued 
normal levels of biomarkers and restored normal functional connectivity. 
 
T21RS, a link between science and society  
Besides being the scientific network for the DS research community, T21RS aims to be a source 
of scientifically-founded information. That is why the Committee for Science & Society has been 
established, led by professor Peter Paul De Deyn (Antwerp, Belgium). The Committee provides 
national and international DS associations with updates on recent scientific discoveries via the 
T21RS Science & Society Bulletin, but also encourages these associations to give feedback and 
point at issues that advocates and participants feel that should be investigated. The special 
T21RS Science & Society Symposium was organized on Sunday 7th of June to (1) more 
extensively introduce T21RS and the Committee for Science & Society to representatives of 
these associations, (2) get acquainted with each other, (3) discuss the gap between science and 
society, and (4) share thoughts and ideas about future directions.  
 Alain Dekker (Groningen, The Netherlands) commenced with a brief introduction to 
T21RS and looked back upon the first year of the society’s existence, including its establishment, 
organizational structure and the latest details on the number of members and their spreading over 
the globe. In the subsequent association introduction round, thirteen associations shortly pitched 
their main goals, initiatives and perspective in three minutes: (1) Alzheimer's Association 
ISTAART Professional Interest Area (PIA): DS-AD (Cindy Lemere, USA), (2) LuMind RDS 
Foundation (Michael Harpold, USA), (3) The Matthew Foundation (John Blascovich and 
Maddalena Adorno, USA), (4) Global Down Syndrome Foundation (Michelle Sie Whitten, 
USA), (5) Fondation Jérome Lejeune (Thierry de la Villejegu, France), (6) Trisomie 21 France 
(Cécile Dupas, France), (7) Down Syndrome international (Andrew Boys, UK), (8a) Down 
España & (8b) European Down Syndrome Association (both represented by Manuel Velázquez 
López, Spain), (9) Fondation AMIPI-Bernard Vendre (Remi Cornubert and Marie-Laure 
Blandin, France), (10) Catalan Down Syndrome Foundation (Sebastián Videla, Spain), (11) 
Association Française pour la Recherche sur la Trisomie 21 (Agnes Duguet, France) and (12) 
Hungarian Down Association (Hungary). 
Next, Peter Paul De Deyn elaborated on the achievements and initiatives of the T21RS 
Committee for Science & Society. One initiative in which the Committee is involved is The 
Dementia Table Initiative in The Netherlands. Sandra Overbeek and Charlotte Toolen (Utrecht, 
The Netherlands) presented their work to set up special evening gatherings, so-called 
DementiaTables, in the twelve provinces of The Netherlands where relatives and caregivers can 
share experiences and improve knowledge about ageing and dementia in people with intellectual 
disabilities. They expanded on the important aspects of the organization and gave tools for 
initiating such sessions in other countries. The positive responses and questions from the 
audience opened the general discussion about Science & Society, which specifically focused on 
closing the gap between science and society, and strengthening and expanding collaborations 
between the Committee and the DS associations. 
 
In summary, the International Conference of the T21RS is poised to become a much needed 
regular, international forum for scientists, clinicians and advocates actively working to improve 
the quality of life of people with DS. Communication and cooperation is the key to continuing 
the truly remarkable progress in a condition that was deemed as “untreatable” just a few years 
ago. 
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